## Miro Venturi Ph.D. Global Head – Diagnostics Biomarkers Hoffmann-la Roche, Basel

After receiving his PhD from the Max-Planck Institute of Biophysics in Frankfurt, Miro specialized in molecular medicine, virology and immunology at the National Institutes of Health, Bethesda, USA. In 2002, Miro joined the pharmaceutical industry as a Biomarker Laboratory Head and project team representative at Pharmacia Corp (later Pfizer Inc.) at the Oncology R&D site located in Nerviano, Italy. In this role, he initially established the biomarker laboratories and actively contributed to the development of numerous oncology programs focusing on small molecular weight kinase inhibitors, including the early development of sunitinib (Sutent) as well as research and exploratory biomarker strategies for several preclinical programs, from lead optimization until PoC clinical studies. In 2005, Miro was invited to join the faculty of the University "Vita Salute San Raffaele" in Milan as Adjunct Professor of preclinical and early clinical development of biopharmaceuticals. In 2007 Miro moved to Novartis as Divisional Head in Biomarker Development, supervising a team of scientists developing assays and supporting project teams in the realization of personalized medicine strategies across the portfolio, with a focus on biologics and oncology programs. His team has contributed to the development of nilotinib (Tasigna) and early programs in both solid tumors and hematological malignancies. Since 2009, Miro joined Roche Oncology where he has contributed the biomarker and personalized medicine strategies and directed the execution for global drug development programs with companion diagnostics, including the development and approval of Perjeta in breast cancer. In 2011, he was appointed Site Head for Oncology Biomarkers within the DTA Oncology Dept, under the leadership of William Pao, and based in Penzberg, Germany. Miro has then been appointed Global Head of Diagnostics Biomarkers at Hoffmann-la Roche and is based at the Company's headquarters in Basel.

Miro has contributed to several drug research and scientific development projects and published in a number of relevant scientific journals, including Nature, Cell, PNAS and others.